Clinical trials: Pharmacokinetic
Healthy Adults
Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants
This is a safety, tolerability, and pharmacokinetic study in 2 cohorts of healthy male participants with an option for an additional cohort.
- Trial name
- NCT04994743
- Testing
- CORT113176
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Hepatic Impairment, Advanced Malignant Solid Tumor
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe…
- Trial name
- NCT04241835
- Testing
- Tazemetostat
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Epizyme, Inc.
Pharmacokinetics and Drug Interaction of Crestor and Glucodown SR
A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers
This clinical trial is designed to compare the pharmacokinetic characteristics of combination and separate administration of Crestor(Rosuvastatin) and Glucodown(Metformin SR).
- Trial name
- NCT01526317
- Testing
- Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Chronic Kidney Disease, Anemia
A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease
The primary objective of this study is to describe how four different dosing regimens of PROCRIT (epoetin alfa) are utilized in patients with anemia due to non-dialysis chronic kidney disease (CKD).
- Trial name
- NCT00641589
- Testing
- epoetin alfa
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating NN1218 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 diabetes.
- Trial name
- NCT01121289
- Testing
- NN1218, insulin aspart
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Novo Nordisk A/S
Partial Epilepsy
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures.
- Trial name
- NCT02535091
- Testing
- YKP3089
- Where
- 121 sites in United States, Argentina and 15 more
- Volunteers
- 1,345 people
- Sponsor
- SK Life Science, Inc.
Contraception
Russia/Ukraine Suppression of Ovarian Activity Study
The purpose of this study is to look into the effectiveness of a new investigational medication applied as a transdermal patch. The patch is applied on the skin with study medication that is absorbed through the skin suppressing…
- Trial name
- NCT02550977
- Testing
- Gestodene/EE Patch (BAY86-5016)
- Where
- 8 sites in Russia, Ukraine
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone
This is a single-center, Phase 1, randomized, double-blind, 6-way crossover study to determine insulin pharmacokinetics, insulin glucodynamics, safety, and tolerability of subcutaneously administered dose(s) of insulin lispro +…
- Trial name
- NCT00979875
- Testing
- Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Analgesia
A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations
A study investigating the pharmacokinetic profiles of four extended release paracetamol formulations
- Trial name
- NCT01568749
- Testing
- Paracetamol, Paracetamol formulation 1, Paracetamol Formulation 2
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects
This study is to investigate the effect of a high fat meal on the pharmacokinetics of decitabine and THU in healthy adults when administered as a modified release formulation of the 2 drugs in combination.
- Trial name
- NCT04086238
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- EpiDestiny, Inc.
Chronic Obstructive Pulmonary Disease
The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations
The objectives of the proposed study are to investigate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and prliminary efficacy of XH-S004 in moderate to severe COPD patients with a stale standards of care…
- Trial name
- NCT07035652
- Testing
- XH-S004 20 mg, 40 mg or 60 mg
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Pediculosis
Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
A pharmacokinetic and tolerance study of Natroba (spinosad) Topical Suspension, 0.9% in pediatric subjects 6 months to 4 years of age with an active head lice infestation.
- Trial name
- NCT01660321
- Testing
- spinosad
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- ParaPRO LLC
Healthy
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2303 and co-administration of each component in fasting condition in healthy volunteers.
- Trial name
- NCT06346184
- Testing
- HCP2303, RLD2302, RLD2102
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes, Diabetes Mellitus, Type 1
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of the trial is to compare pharmacokinetics (at which rate the body eliminates the substance from the body) of insulin aspart with fast-acting insulin human following intravenous (IV)…
- Trial name
- NCT01269606
- Testing
- insulin aspart, insulin human
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
Diffuse Large B-cell Lymphoma
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05192486
- Testing
- GNC-038
- Where
- 4 sites in China
- Volunteers
- 12 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
The study will contain three stages: Phase I includes dose escalation phase (i.e., phase Ia) and dose expansion phase (i.e., phase Ib).
- Trial name
- NCT06590194
- Testing
- PH009-1 tablet
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTD
HIV Infections
Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in…
- Trial name
- NCT00885495
- Testing
- darunavir, ritonavir, rosuvastatin, rosuvastatin, darunavir, ritonavir
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Chronic Obstructive Pulmonary Disease
A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the systemic exposure and pharmacodynamics of two doses of nebulized fluticasone/formoterol combination as compared to the monocomponents.
- Trial name
- NCT00774761
- Testing
- fluticasone propionate/formoterol fumarate, fluticasone propionate, formoterol fumarate
- Where
- 12 sites in United States
- Volunteers
- 97 people
- Sponsor
- Dey
Renal Failure, Critical Care
Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure
Treatment of infections in critically ill patients remains a significant challenge to intensivists world-wide with persisting high mortality and morbidity.
- Conditions
- Renal Failure, Critical Care, Gram Positive Bacteria
- Trial name
- DAPTOREA (NCT02142075)
- Testing
- Daptomycin
- Where
- 4 sites in France
- Sponsor
- Poitiers University Hospital
Advanced/Metastatic Solid Tumors
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and…
- Trial name
- NCT06922357
- Testing
- HRS-6719
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.